These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://iwandqby716365.estate-blog.com/38022209/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide